Related Experiment Videos
[Hemodynamics and ventricular function in dilated cardiomyopathies following administration of the new beta-blocker
Insights
This study found that the beta-blocker ridazolol did not negatively impact left ventricular function or hemodynamics in patients with dilated cardiomyopathy (DCMP). Ridazolol appears suitable for further investigation in DCMP treatment.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Dilated cardiomyopathy (DCMP) is a condition where the heart's main pumping chamber weakens.
- Beta-blockers are being investigated for their potential to improve survival in DCMP patients.
Purpose:
- To assess the hemodynamic suitability of the novel beta-blocker ridazolol in patients with DCMP.
- To evaluate the effects of ridazolol on left ventricular function and hemodynamics at rest and during exercise.
Summary:
- Nine patients with DCMP (NYHA class II/III) received a 40 mg oral dose of ridazolol.
- Hemodynamic assessments (pulmonary artery catheter, radionuclide ventriculography) were performed before and after administration.
- Ridazolol showed a trend towards decreasing blood pressure and heart rate without significantly altering pulmonary capillary wedge pressure or ejection fraction at rest or during exercise.
Impact:
- Ridazolol did not demonstrate deleterious effects on left ventricular function or hemodynamics in this small cohort.
- These findings suggest ridazolol may be a potential candidate for further clinical trials in managing dilated cardiomyopathy.
Abstract:
Recent reports in the literature indicate that beta-blockade may improve survival in patients with dilated cardiomyopathy (DCMP). This goal can obviously not be attained if the beta-blocker employed effects deleterious actions on the left ventricular function or hemodynamics. Accordingly, to assess the suitability of the new beta-blocker ridazolol for use in this regard, in nine patients with DCMP NYHA class II/III, studies were performed (by means of balloon-tipped pulmonary artery catheter and radionuclide ventriculography) at rest and during exercise prior to and one hour after oral administration of a 40 mg-dose of the agent. At rest, there was a decreasing tendency in systolic blood pressure from 123 +/- 18.5 mm Hg to 113 +/- 15.2 mm Hg and heart rate from 94 +/- 19 beats/min to 83 +/- 17 beats/min. Pulmonary capillary wedge pressure was not significantly altered at 16.2 +/- 7.9 mm Hg and 17.1 +/- 8.4 mm Hg, respectively. Ejection fraction remained unchanged with 29 +/- 14%. The slight decrease in cardiac output from 5.1 +/- 1.3 l/min to 4.5 +/- 1.3 l/min was not significant. During exercise, there were also decreasing tendencies in the heart rate from 128 +/- 21 beats/min to 102 +/- 22 beats/min and the systolic blood pressure from 148 +/- 20.5 mm Hg to 141 +/- 18.4 mm Hg. Essentially unchanged were the pulmonary capillary wedge pressure (26.1 +/- 7.2 mm Hg/27.8 +/- 5.0 mm Hg) and ejection fraction (30 +/- 10%/27 +/- 8%) during exercise.(ABSTRACT TRUNCATED AT 250 WORDS)